Brian L. Black, Karel van Duijvenboden, Stephanie Protze, Michael D. Wilson, Corrie de Gier-de Vries, Rajiv A Mohan, Vincent W. W. van Eif, Arie O. Verkerk, Fernanda M Bosada, Tanvi Sinha, Ian C. Scott, Auriane C. Ernault, Jeroen Bakkers, Xuefei Yuan, Vincent Wakker, Bastiaan J. Boukens, Ingeborg B. Hooijkaas, Vincent M. Christoffels, Hubrecht Institute for Developmental Biology and Stem Cell Research, Graduate School, Medical Biology, ACS - Heart failure & arrhythmias, ARD - Amsterdam Reproduction and Development, Cardiology, ACS - Pulmonary hypertension & thrombosis, ACS - Amsterdam Cardiovascular Sciences, Hôpital Nord [CHU - APHM], Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Netherlands Scientific Organization ZonMW TOP 40-00812-98-12086Leducq Foundation 14CVD01Netherlands Heart Foundation 2013T091 2016T047Fondation pour la Recherche Medicale PBR201810007613Canadian Institutes of Health Research (CIHR) FRN 86663 FRN 156318United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA HL064658 HL136182
Rationale: The development and function of the pacemaker cardiomyocytes of the sinoatrial node (SAN), the leading pacemaker of the heart, are tightly controlled by a conserved network of transcription factors, including TBX3 (T-box transcription factor 3), ISL1 (ISL LIM homeobox 1), and SHOX2 (short stature homeobox 2). Yet, the regulatory DNA elements (REs) controlling target gene expression in the SAN pacemaker cells have remained undefined. Objective: Identification of the regulatory landscape of human SAN-like pacemaker cells and functional assessment of SAN-specific REs potentially involved in pacemaker cell gene regulation. Methods and Results: We performed Assay for Transposase-Accessible Chromatin using sequencing on human pluripotent stem cell–derived SAN-like pacemaker cells and ventricle-like cells and identified thousands of putative REs specific for either human cell type. We validated pacemaker cell–specific elements in the SHOX2 and TBX3 loci. CRISPR-mediated homozygous deletion of the mouse ortholog of a noncoding region with candidate pacemaker-specific REs in the SHOX2 locus resulted in selective loss of Shox2 expression from the developing SAN and embryonic lethality. Putative pacemaker-specific REs were identified up to 1 Mbp upstream of TBX3 in a region close to MED13L harboring variants associated with heart rate recovery after exercise. The orthologous region was deleted in mice, which resulted in selective loss of expression of Tbx3 from the SAN and (cardiac) ganglia and in neonatal lethality. Expression of Tbx3 was maintained in other tissues including the atrioventricular conduction system, lungs, and liver. Heterozygous adult mice showed increased SAN recovery times after pacing. The human REs harboring the associated variants robustly drove expression in the SAN of transgenic mouse embryos. Conclusions: We provided a genome-wide collection of candidate human pacemaker-specific REs, including the loci of SHOX2 , TBX3 , and ISL1 , and identified a link between human genetic variants influencing heart rate recovery after exercise and a variant RE with highly conserved function, driving SAN expression of TBX3 .